Open data 5 years on: A case series of 12 freedom of information requests for regulatory data to the European Medicines Agency

Trials

Volumn 17, Issue 1, 2016, Pages

  Doshi, Peter ^a   Jefferson, Tom ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b Cochrane Acute Respiratory Infections Group ^*  (Italy)

Author keywords

Access to documents; Clinical study report; Cochrane collaboration; CSR; EMA; European medicines agency; Evidence synthesis; Freedom of information; Freedom of information act; Publication bias; Regulatory science; Reporting bias; Systematic reviews

Indexed keywords

CASE STUDY; CLINICAL TRIAL; DECISION MAKING; EUROPEAN MEDICINES AGENCY; HUMAN; IDENTIFIABLE INFORMATION; SCIENTIST; WRITING; ACCESS TO INFORMATION; CLINICAL TRIAL (TOPIC); EUROPE; LEGISLATION AND JURISPRUDENCE; TIME FACTOR;

ACCESS TO INFORMATION; CLINICAL TRIALS AS TOPIC; EUROPE; HUMANS; TIME FACTORS;

EID: 84957867278     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-016-1194-7     Document Type: Article

References (21)

1. Doshi P, Jefferson T. Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports. BMJ Open. 2013;3(2):e002496.
2. Chalmers I. Underreporting research is scientific misconduct. JAMA. 1990;263(10):1405-8.
3. AllTrials. All trials registered. All results reported [Internet]. AllTrials. Available from: http://www.alltrials.net/. Accessed 18 August 2015.
4. Spelsberg A. Petition Berliner Erklärung 2012: An die Bürgerinnen und Bürger in Europa: Die Verheimlichung von klinischen Studiendaten stoppen Change.org [Internet]. 2012. Available from: https://www.change.org/p/berliner-erkl%C3%A4rung-2012-an-die-b%C3%BCrgerinnen-und-b%C3%BCrger-in-europa-die-verheimlichung-von-klinischen-studiendaten-stoppen. Accessed 18 August 2015.
5. European Medicines Agency. European Medicines Agency policy on access to documents (related to medicinal products for human and veterinary use) POLICY/0043 [Internet]. 2010. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/11/WC500099473.pdf. Accessed 18 August 2015.
6. PhRMA, EFPIA. Principles for responsible clinical trial data sharing [Internet]. 2013. Available from: http://phrma.org/sites/default/files/pdf/PhRMAPrinciplesForResponsibleClinicalTrialDataSharing.pdf. Accessed 1 August 2013.
7. Institute of Medicine. Sharing clinical trial data: maximizing benefits, minimizing risk. Washington, DC: The National Academies Press; 2015.
8. Barron H, Rosenblatt M. Access to patient-level trial data. N Engl J Med. 2014;370(5):485-6.
9. Nisen P, Rockhold F. Access to patient-level data from GlaxoSmithKline clinical trials. N Engl J Med. 2013;369(5):475-8.
10. Moorthy VS, Karam G, Vannice KS, Kieny M-P. Rationale for WHO's new position calling for prompt reporting and public disclosure of interventional clinical trial results. PLoS Med. 2015;12(4):e1001819.
11. World Health Organization. WHO Statement on Public Disclosure of Clinical Trial Results [Internet]. WHO. 2015. Available from: http://www.who.int/ictrp/results/reporting/en/. Accessed 18 August 2015.
12. European Medicines Agency. Send a question to the European Medicines Agency [Internet]. 2015. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/landing/ask_ema_landing_page.jsp&mid=WC0b01ac05806499f0. Accessed 18 August 2015.
13. European Medicines Agency. Release of data from clinical trials [Internet]. 2012. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000555.jsp&mid=WC0b01ac0580607bfa. Accessed 27 November 2012.
14. European Medicines Agency. European Medicines Agency policy on publication of clinical data for medicinal products for human use [Internet]. 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2013/06/WC500144730.pdf. Accessed 24 June 2013.
15. Doshi P, Jefferson T. The first 2 years of the European Medicines Agency's policy on access to documents: secret no longer. JAMA Intern Med. 2013;173(5):380-2.
16. Doshi P. Transparency interrupted: the curtailment of the European Medicines Agency's policy on access to documents. JAMA Intern Med [Internet]. 2013. Available from: http://dx.doi.org/10.1001/jamainternmed.2013.9989. Accessed 20 August 2013.
17. European Medicines Agency. Guide on access to unpublished documents [Internet]. 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2013/06/WC500144730.pdf. Accessed 17 August 2015.
18. European Medicines Agency. European Medicines Agency finalises review of medicines concerned by Roche pharmacovigilance inspection [Internet]. 2013. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/11/news_detail_001962.jsp&mid=WC0b01ac058004d5c1. Accessed 18 August 2015.
19. Jefferson T, Jones MA, Doshi P, Del Mar CB, Heneghan CJ, Hama R, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2012;1:CD008965.
20. Doshi P, Jones M, Jefferson T. Rethinking credible evidence synthesis. BMJ. 2012;344:d7898.
21. European Medicines Agency. European Medicines Agency starts infringement procedure to investigate Roche's alleged non-compliance with pharmacovigilance obligations [Internet]. 2012. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/10/news_detail_001641.jsp&mid=WC0b01ac058004d5c1. Accessed 7 November 2012.